Valneva rises on positive mid-stage study data of chikungunya vaccine in children

Valneva SE

05/06/2025 17:44

** U.S.-listed shares of French vaccine company Valneva VLS.PA, VALN.O rise 3.2% to $6.45

** Co says its chikungunya vaccine, Ixchiq, was well tolerated by children aged one to eleven years, regardless of the dose or previous chikungunya infection, in a mid-stage study with 304 children

** Chikungunya is a mosquito-borne viral disease spread by the bites of infected type of mosquitoes that causes fever, severe joint and muscle pain, headache, nausea, fatigue and rash

** Co expects to begin late-stage study in Q1 2026

** Says the immunological response profile of the drug was in line with what was previously observed in  adults and adolescents

** Including session's move, stock up 47.5% YTD

(Reporting by Siddhi Mahatole)

((siddhi.mahatole@thomsonreuters.com))